Two Sigma Securities’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Two Sigma Securities’s Portfolio IMUC Stock Details IMUC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-61,448	Closed	-$13K	–	3182
2018 Q3	$13K	Buy	+61,448	New	+$14.2K	﹤0.01%	2487
2018 Q2	–	Sell	-39,231	Closed	-$10K	–	3228
2018 Q1	$10K	Buy	+39,231	New	+$10.8K	﹤0.01%	2613
2017 Q4	–	Sell	-14,600	Closed	-$5K	–	2186
2017 Q3	$5K	Buy	+14,600	New	+$7.1K	﹤0.01%	881
2016 Q4	–	Sell	-515	Closed	-$2K	–	1100
2016 Q3	$2K	Buy	+515	New	+$3.31K	﹤0.01%	643

Other funds holding IMUC

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

Two Sigma Securities's IMUC Position: Q4 2018 in Review

Two Sigma Securities sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2018, closing a stake of 61,448 shares — an estimated $13K sold.

Two Sigma Securities first reported a position in IMUC in Q3 2016 and held it in 4 quarters. The position peaked at $13K in Q3 2018. 3 funds tracked by Wall St. Rank hold IMUC as of Q4 2018.

Two Sigma Securities reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2018 after selling out during the quarter.
Two Sigma Securities sold 61,448 ImmunoCellular Therapeutics, Ltd. shares in Q4 2018, an estimated $13K.
Two Sigma Securities first reported a position in ImmunoCellular Therapeutics, Ltd. in Q3 2016 and held it in 4 quarters.
Two Sigma Securities's ImmunoCellular Therapeutics, Ltd. position peaked at $13K in Q3 2018.
3 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2018.

Based on Two Sigma Securities's 13F filing for Q4 2018, filed 14 Feb 2019.